LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist B in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset (ID:20359)
Download: Excel (XLSX), Comma-separated (CSV)
| Small Molecule | barcode | cell_count | frac_dead | corpse_count | cell_count_dead | row | column | agent | concentration | role | timepoint | replicate | cell_line | dead_count | fraction_dead | cell_count__time0 | dead_count__time0 | cell_count__ctrl | dead_count__ctrl | fraction_dead__ctrl | increase_fraction_dead | GRvalue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Etoposide | 180614_BG_04 | 15294 | 0.0192 | 118 | 178 | 9 | 14 | Etoposide | 0.033266667 | treatment | 72 | 1 | MCF10A-GM_9 | 296 | 0.0190 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | -0.00101 | 0.9495 |
| Etoposide | 180614_BG_04 | 1143 | 0.1317 | 102 | 62 | 12 | 4 | Etoposide | 3.193598006 | treatment | 72 | 1 | MCF10A-GM_9 | 164 | 0.1255 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.10548 | 0.0608 |
| Dasatinib | 180614_BG_04 | 1785 | 0.2705 | 167 | 361 | 11 | 11 | Dasatinib | 3.193598006 | treatment | 72 | 1 | MCF10A-GM_9 | 528 | 0.2283 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.20828 | 0.1777 |
| Etoposide | 180614_BG_04 | 16289 | 0.0178 | 92 | 199 | 12 | 17 | Etoposide | 0.00998 | treatment | 72 | 1 | MCF10A-GM_9 | 291 | 0.0176 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | -0.00244 | 0.9786 |
| Etoposide | 180614_BG_04 | 1441 | 0.1836 | 198 | 103 | 11 | 9 | Etoposide | 0.997999808 | treatment | 72 | 1 | MCF10A-GM_9 | 301 | 0.1728 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.15279 | 0.1200 |
| Dasatinib | 180614_BG_04 | 16850 | 0.0209 | 128 | 226 | 9 | 9 | Dasatinib | 0.033266667 | treatment | 72 | 1 | MCF10A-GM_9 | 354 | 0.0206 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.00058 | 0.9944 |
| Dasatinib | 180614_BG_04 | 6492 | 0.0423 | 128 | 152 | 14 | 17 | Dasatinib | 0.316033316 | treatment | 72 | 1 | MCF10A-GM_9 | 280 | 0.0413 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.02135 | 0.5944 |
| Dasatinib | 180614_BG_04 | 4617 | 0.0845 | 140 | 262 | 12 | 11 | Dasatinib | 0.997999808 | treatment | 72 | 1 | MCF10A-GM_9 | 402 | 0.0801 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.06010 | 0.4719 |
| Dasatinib | 180614_BG_04 | 16506 | 0.0206 | 110 | 233 | 11 | 19 | Dasatinib | 0.003326667 | treatment | 72 | 1 | MCF10A-GM_9 | 343 | 0.0204 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.00036 | 0.9847 |
| Etoposide | 180614_BG_04 | 17213 | 0.0261 | 124 | 328 | 14 | 8 | Etoposide | 0.003326667 | treatment | 72 | 1 | MCF10A-GM_9 | 452 | 0.0256 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.00559 | 1.0044 |
| Etoposide | 180614_BG_04 | 10954 | 0.0271 | 163 | 138 | 11 | 17 | Etoposide | 0.099799999 | treatment | 72 | 1 | MCF10A-GM_9 | 301 | 0.0267 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.00675 | 0.8027 |
| Etoposide | 180614_BG_04 | 5586 | 0.0357 | 94 | 109 | 10 | 11 | Etoposide | 0.316033316 | treatment | 72 | 1 | MCF10A-GM_9 | 203 | 0.0351 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.01507 | 0.5392 |
| Alpelisib | 180614_BG_04 | 10966 | 0.0276 | 140 | 167 | 14 | 21 | Alpelisib | 3.193598006 | treatment | 72 | 1 | MCF10A-GM_9 | 307 | 0.0272 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.00724 | 0.8031 |
| Dasatinib | 180614_BG_04 | 16384 | 0.0227 | 153 | 222 | 9 | 11 | Dasatinib | 0.00998 | treatment | 72 | 1 | MCF10A-GM_9 | 375 | 0.0224 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.00238 | 0.9813 |
| Alpelisib | 180614_BG_04 | 6841 | 0.0354 | 169 | 79 | 14 | 14 | Alpelisib | 9.98 | treatment | 72 | 1 | MCF10A-GM_9 | 248 | 0.0350 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.01499 | 0.6142 |
| Dasatinib | 180614_BG_04 | 12291 | 0.0237 | 117 | 177 | 12 | 8 | Dasatinib | 0.099799999 | treatment | 72 | 1 | MCF10A-GM_9 | 294 | 0.0234 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.00337 | 0.8521 |
| Alpelisib | 180614_BG_04 | 16325 | 0.0255 | 114 | 305 | 14 | 10 | Alpelisib | 0.00998 | treatment | 72 | 1 | MCF10A-GM_9 | 419 | 0.0250 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.00503 | 0.9796 |
| Alpelisib | 180614_BG_04 | 16461 | 0.0158 | 45 | 215 | 13 | 22 | Alpelisib | 0.003326667 | treatment | 72 | 1 | MCF10A-GM_9 | 260 | 0.0155 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | -0.00445 | 0.9835 |
| Alpelisib | 180614_BG_04 | 15509 | 0.0170 | 80 | 185 | 12 | 22 | Alpelisib | 0.316033316 | treatment | 72 | 1 | MCF10A-GM_9 | 265 | 0.0168 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | -0.00320 | 0.9559 |
| Alpelisib | 180614_BG_04 | 16458 | 0.0192 | 110 | 208 | 9 | 15 | Alpelisib | 0.033266667 | treatment | 72 | 1 | MCF10A-GM_9 | 318 | 0.0190 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | -0.00104 | 0.9834 |
| Dasatinib | 180614_BG_04 | 811 | 0.5853 | 127 | 422 | 11 | 16 | Dasatinib | 9.98 | treatment | 72 | 1 | MCF10A-GM_9 | 549 | 0.4037 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.38368 | -0.0213 |
| Alpelisib | 180614_BG_04 | 12183 | 0.0243 | 128 | 171 | 7 | 18 | Alpelisib | 0.997999808 | treatment | 72 | 1 | MCF10A-GM_9 | 299 | 0.0240 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.00396 | 0.8482 |
| Alpelisib | 180614_BG_04 | 16091 | 0.0216 | 111 | 239 | 6 | 5 | Alpelisib | 0.099799999 | treatment | 72 | 1 | MCF10A-GM_9 | 350 | 0.0213 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.00129 | 0.9729 |
| Neratinib | 180614_BG_04 | 14330 | 0.0207 | 92 | 206 | 13 | 16 | Neratinib | 0.001081167 | treatment | 72 | 1 | MCF10A-GM_9 | 298 | 0.0204 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.00038 | 0.9200 |
| Etoposide | 180614_BG_04 | 1094 | 0.2332 | 227 | 81 | 13 | 12 | Etoposide | 9.98 | treatment | 72 | 1 | MCF10A-GM_9 | 308 | 0.2197 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.19969 | 0.0499 |